Obrixtamig + ZL-1310 for Small Cell Lung Cancer

This trial explores a new combination of treatments to combat advanced small cell lung cancer and other neuroendocrine cancers. The study occurs in two parts. Part 1 aims to determine the right dose of two potential drugs, obrixtamig and ZL-1310. Part 2 introduces another medicine to assess the combination's effectiveness and patient tolerance. Individuals with advanced small cell lung cancer who haven't responded to other treatments might be suitable candidates. As a Phase 1/Phase 2 trial, this research seeks to understand how the treatment works in people and measure its effectiveness in an initial, smaller group, offering patients a chance to benefit from these new therapies.

The trial protocol does not specify if you need to stop taking your current medications. However, it mentions restrictions regarding prohibited medications, so it's best to discuss your current medications with the trial team.

Research has shown that the combination of obrixtamig and ZL-1310 is generally safe for humans. A previous study found no severe side effects, such as serious immune reactions or brain-related issues, in patients taking ZL-1310. Most side effects were mild to moderate, including nausea or tiredness.

Researchers are excited about Obrixtamig + ZL-1310 because this combination offers a novel approach to treating small cell lung cancer. Unlike traditional chemotherapy, which targets all rapidly dividing cells, this treatment specifically targets cancer cells, potentially reducing side effects and increasing effectiveness. The inclusion of atezolizumab in Part 2 aims to enhance the immune system's ability to fight cancer, a promising strategy not commonly used in current standard treatments. This targeted approach and the potential to combine with immunotherapy could lead to improved outcomes for patients.

Research shows that combining obrixtamig and ZL-1310 may help treat small cell lung cancer. In earlier studies, ZL-1310 alone achieved a 74% success rate in shrinking tumors in patients with advanced small cell lung cancer. Obrixtamig, the other drug in the combination, demonstrated a 54% success rate in treating another type of cancer, suggesting potential effectiveness. In this trial, participants will receive either obrixtamig and ZL-1310 in different dosing regimens or the combination of obrixtamig, ZL-1310, and atezolizumab. When used with atezolizumab, a medicine that helps the immune system fight cancer, studies found the treatment generally safe and free of unexpected side effects. These results suggest that this combination could effectively control cancer growth.⁶⁷⁸⁹¹⁰